C07K 14/50
Fibroblast growth factor [fgf]
Official title: Fibroblast growth factor [FGF]
C07K14/50 (Fibroblast growth factor [fgf]) appears on 744 US grants and 967 published applications in this corpus.
Search patents in C07K- Granted patents
- 744
- Published applications
- 967
- Assignees
- 409
- Inventors
- 1,768
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 13 | 0 |
| 1993 | 15 | 0 |
| 1994 | 12 | 0 |
| 1995 | 14 | 0 |
| 1996 | 13 | 0 |
| 1997 | 19 | 0 |
| 1998 | 35 | 0 |
| 1999 | 28 | 0 |
| 2000 | 18 | 0 |
| 2001 | 17 | 6 |
| 2002 | 19 | 39 |
| 2003 | 17 | 52 |
| 2004 | 26 | 53 |
| 2005 | 6 | 40 |
| 2006 | 22 | 24 |
| 2007 | 24 | 29 |
| 2008 | 13 | 26 |
| 2009 | 21 | 38 |
| 2010 | 30 | 32 |
| 2011 | 19 | 25 |
| 2012 | 20 | 28 |
| 2013 | 23 | 39 |
| 2014 | 19 | 32 |
| 2015 | 28 | 30 |
| 2016 | 35 | 46 |
| 2017 | 21 | 48 |
| 2018 | 36 | 44 |
| 2019 | 22 | 42 |
| 2020 | 21 | 46 |
| 2021 | 23 | 45 |
| 2022 | 25 | 35 |
| 2023 | 25 | 45 |
| 2024 | 21 | 59 |
| 2025 | 20 | 39 |
| 2026 | 17 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method of preparing circular permutation-based functional recombinant human-derived fibroblast growth factor 7 and use thereof15 Sep 2026US 12,735,465 B2Industry Foundation of Chonnam National University
- Fusion protein having triple activity and use thereof8 Sep 2026US 12,729,231 B2Shanghai Minwei Biotechnology Co., LTD
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant fc fusion proteins25 Aug 2026US 12,714,739 B2Novartis AG
- Production method for organoid30 Jun 2026US 12,668,773 B2Jsr Corporation
- FGF21 compositions for treatment or prevention of neovascularization of the eye and methods therefor16 Jun 2026US 12,653,863 B2Children's Medical Center Corporation
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Recombinant modified fibroblast growth factors and therapeutic uses thereof10 Sep 2026US 2026/0265323 A1Trefoil Therapeutics, Inc.
- Sfgf1-fgf21: a chimeric protein with increased stability and biological activities27 Aug 2026US 2026/0250340 A1
- Microbial production of growth factors27 Aug 2026US 2026/0250341 A1Dsm IP Assets B.V.
- De novo designed cyclic oligomeric proteins13 Aug 2026US 2026/0234209 A1New York University
Most cited
By later US patents
- Supplemented and unsupplemented tissue sealants, methods of their production and use441US 6,197,325 B1American National Red Cross · 2001
- Positive-negative selection methods and vectors410US 5,464,764 AUniversity of Utah Research Foundation · 1995
- Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same308US 5,487,992 AUniversity of Utah Research Foundation · 1996
- Supplemented and unsupplemented tissue sealants, methods of their production and use292US 6,054,122 AAmerican National Red Cross · 2000
- Cationic lipids and the use thereof249US 5,830,430 AImaRx Pharmaceutical Corp. · 1998